<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Buscema, Marzia</dc:creator>
  <dc:creator>Matviykiv, Sofiya</dc:creator>
  <dc:creator>Mészáros, Tamás</dc:creator>
  <dc:creator>Gerganova, Gabriela</dc:creator>
  <dc:creator>Weinberger, Andreas</dc:creator>
  <dc:creator>Mettal, Ute</dc:creator>
  <dc:creator>Mueller, Dennis</dc:creator>
  <dc:creator>Neuhaus, Frederik</dc:creator>
  <dc:creator>Stalder, Etienne</dc:creator>
  <dc:creator>Ishikawa, Takashi</dc:creator>
  <dc:creator>Urbanics, Rudolf</dc:creator>
  <dc:creator>Saxer, Till</dc:creator>
  <dc:creator>Pfohl, Thomas</dc:creator>
  <dc:creator>Szebeni, János</dc:creator>
  <dc:creator>Zumbuehl, Andreas</dc:creator>
  <dc:creator>Müller, Bert</dc:creator>
  <dc:date>2017-10-28</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Liposomes formulated from the 1,3-diamidophospholipid Pad-PC-Pad are shear- responsive and thus promising nano-containers to specifically release a vasodilator at  stenotic arteries. The recommended preclinical safety tests for therapeutic liposomes  of nanometer size include the in vitro assessment of complement activation and the  evaluation of the associated risk of complement activation-related pseudo-allergy  (CARPA) in vivo. For this reason, we measured complement activation by Pad-PC- Pad formulations in human and porcine sera, along with the nanopharmaceutical- mediated cardiopulmonary responses in pigs. The evaluated formulations comprised  of Pad-PC-Pad liposomes, with and without polyethylene glycol on the surface of the  liposomes, and nitroglycerin as a model vasodilator. The nitroglycerin incorporation  efficiency ranged from 25% to 50%. In human sera, liposome formulations with 20  mg/mL phospholipid gave rise to complement activation, mainly via the alternative  pathway, as reflected by the rises in SC5b-9 and Bb protein complex concentrations.  Formulations having a factor of ten lower phospholipid content did not result in  measurable complement activation. The weak complement activation induced by Pad- PC-Pad liposomal formulations was confirmed by the results obtained by performing  an in vivo study in a porcine model, where hemodynamic parameters were monitored  continuously. Our study suggests that, compared to FDA-approved liposomal drugs,  Pad-PC-Pad exhibits less or similar risks of CARPA.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/305966</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/305966/files/zue_irn.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/305966/files/zue_irn_sm.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jconrel.2017.08.010</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Journal of Controlled Release. - 2017, vol. 264, no. Supplement C, p. 14–23</dc:source>
  <dc:subject>info:eu-repo/classification/udc/54</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Immunological response to nitroglycerin-loaded shear-responsive liposomes in vitro and in vivo</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
